Doximity, Inc.
HealthcareNYSE:DOCS · New York Stock Exchange
+$0.02 today
Vol 1.98M · Avg 3.86M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
20.6%
avg 349.5%
ROIC
17.4%
avg 17.9%
ROA
17.4%
avg 15.6%
Analysis
ROE is currently the strongest return metric at 20.6% versus its period average of 349.5%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jeffrey A. Tangney | Co-Founder, Chief Executive Officer & Chairperson | $1.80M | — | 53 | $2.56M | 1.37% |
Matthew Sonefeldt | Chief Financial Officer | $825,394.00 | — | 46 | — | — |
Anna Bryson | Chief Financial Officer | $825,394.00 | — | 36 | $516,930.00 | 0.28% |
Nathan Gross | Advisor & Co-Founder | $526,243.00 | — | 42 | — | — |
Craig A. Overpeck | Senior Vice President of Commercial Operations | $306,349.00 | — | — | $108,609.00 | 0.06% |
Steven L. Zatz | President | — | — | 69 | $17,950.00 | <0.01% |
John Vaughan | General Counsel, Corporate Secretary & Chief Compliance Officer | — | — | — | — | — |
Ben Greenberg | Senior Vice President & GM Commercial Products | — | — | — | — | — |
Bruno Miranda | Senior Vice President of Engineering | — | — | — | — | — |
Jey Balachandran | Chief Technology Officer | — | — | — | — | — |
Joel Davis | Senior Vice President of Product | — | — | — | — | — |
Perry Scott Gold | Head of Investor Relations | — | — | — | — | — |
Siddharth Sitaram | Chief Accounting Officer and Interim Principal Financial & Accounting Officer | — | — | — | $5,000.00 | <0.01% |
Lisa Greenbaum | Chief Commercial Officer | — | — | 54 | — | — |
Shari Buck | Co-founder and SVP People & Ops | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
27
$10.37M
Net Sentiment
$10.37M
Net selling
Most Active
Wampler Kira Scherer
10 transactions
1–10 of 27
Analysis
Insiders reported 0 buys worth $0.00 and 27 sells worth $10.37M over the last 12 months. That adds up to net selling of $10.37M. Wampler Kira Scherer was the most active insider with 10 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +107.2% | +18.8% (8yr)1 analysts |
| Revenue | N/A | N/A | +53.3% | +8.6% (8yr)2 analysts |
| Net Income | N/A | N/A | +56.0% | +17.8% (8yr)2 analysts |
| EBIT | N/A | N/A | +78.1% | +12.2% (8yr)2 analysts |
Analysis
Recent growth has been strongest in EPS at +107.2% over three years. Forward estimates point to EPS at +18.8% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Exact Sciences Corporation
EXAS
$20.03B
Viatris Inc.
NASDAQ:VTRS
$19.19B
Guardant Health, Inc.
NASDAQ:GH
$17.45B
Solventum Corporation
NYSE:SOLV
$13.66B
The Cooper Companies, Inc.
NASDAQ:COO
$13.24B
ICON Public Limited Company
NASDAQ:ICLR
$11.19B
Revvity, Inc.
NYSE:RVTY
$11.12B
Encompass Health Corporation
NYSE:EHC
$10.07B
Tempus AI, Inc.
NASDAQ:TEM
$8.35B
HealthEquity, Inc.
NASDAQ:HQY
$7.39B
Who manages DOCS?
Doximity, Inc. (DOCS) lists 15 active executives. The top listed executive is Nathan Gross, Advisor & Co-Founder.
Are DOCS insiders buying or selling?
Recent insider activity shows net selling of $21.82M.
Explore More
Continue the stock analysis
Jump to another research area for this company.